Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
688091 Shanghai Yizhong Pharmaceutical
73.250
+3.840+5.53%
All
YOY
Do not show
Product Unit:CNY

Loading...

Industry Unit:CNY

Loading...

Region Unit:CNY

Loading...

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

Company Overview More
The company is committed to the development of new dosage forms of antineoplastic drugs and related products. The company is committed to the R & D and industrialization of improved new drugs for antineoplastic drugs, with high-tech talents with the background of polymer materials, pharmaceutical preparations and biology, and mastering the core and key technologies for the synthesis of nano-drug carriers and medicinal polymer excipients. The company's main research and development product is paclitaxel micelles. Paclitaxel micelle is an innovative lyophilized powder injection without polyoxyethylene castor oil and methoxy polyethylene glycol 2000-poly (lactide) copolymer as carrier.
CEO: Jingsong Zhou
Market: --
Listing Date: 09/09/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist